GlassScriptPhysician profile
Michael S Friedman
NPI 1962562355
$6,355.33
in general payments reported to CMS, 2019-2025
37 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $522 · 2021: $945 · 2022: $955 · 2023: $1,560 · 2024: $1,150 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.68 | 2021-2025 | |
| Novo Nordisk INC | $1,100.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $771.64 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $387.39 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $323.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $301.75 | 2019-2024 | Breztri |
| Allergan, INC. | $253.84 | 2019-2020 | |
| Lilly USA, LLC | $214.30 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $206.03 | 2022-2024 | Rexulti |
| Dexcom, INC. | $176.50 | 2021-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.85 | 2020-2024 | Xifaxan, Trulance |
| Eisai INC. | $123.89 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $100.90 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $91.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $87.16 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.